Meridian Bioscience (VIVO) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $1.66 +3.75%
Financial Fact:
INCOME TAX PROVISION: 3.26M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
INCOME TAX PROVISION: 3.26M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.13, $0.02 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $49 million versus the consensus estimate of $48.05 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- VivoPower Reports FY2026 Results Including a Partial-Period Contribution from Mo i Rana Data Center
- Datadog stock tumbles 19% despite earnings beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
